AstraZeneca's CEO, Pascal Soriot, emphasizes the need for Western pharmaceutical companies to adopt a faster pace of innovation, akin to that of China's rapidly advancing drug industry. He warns that without this shift, they risk losing competitiveness, similar to the challenges faced by the Western automotive sector.
Soriot highlighted AstraZeneca's commitment to achieving ambitious growth targets, aiming for $80 billion in annual sales by 2030. The company reported a 6% revenue increase in the first half of 2026, despite setbacks in clinical trials for some of its drug candidates. He acknowledged the inevitability of failures in drug development, emphasizing that understanding biology is crucial in this field.
Furthermore, Soriot pointed out the significant investments being made by Chinese pharmaceutical firms in innovative technologies, such as antibody drug conjugates and cell therapies. He believes that the Western industry must remain vigilant to these developments to maintain its market position.
On the topic of artificial intelligence, Soriot downplayed fears regarding job losses, suggesting that AI can enhance productivity and accelerate drug development processes rather than replace human roles. He expressed optimism about AI's potential to streamline operations within the pharmaceutical sector.
Looking ahead, AstraZeneca plans to engage with the UK government regarding a controversial healthcare deal with the US, which could have substantial financial implications for the NHS. Soriot emphasized the need for clear priorities in funding and healthcare strategy moving forward.